These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 28820069)

  • 1. Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure.
    Cortese F; Scicchitano P; Gesualdo M; Ricci G; Carbonara S; Franchini C; Pia Schiavone BI; Corbo F; Ciccone MM
    Curr Med Chem; 2017 Nov; 24(34):3813-3827. PubMed ID: 28820069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
    Altawalbeh SM; Alshogran OY; Smith KJ
    Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
    Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
    JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
    Pujadas-Mestres L; Escolar G; Arellano-Rodrigo E; Galán AM
    Drugs Today (Barc); 2013 Jul; 49(7):425-36. PubMed ID: 23914351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.
    Melloni C; Dunning A; Granger CB; Thomas L; Khouri MG; Garcia DA; Hylek EM; Hanna M; Wallentin L; Gersh BJ; Douglas PS; Alexander JH; Lopes RD
    Am J Med; 2017 Dec; 130(12):1440-1448.e1. PubMed ID: 28739198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Hohnloser SH; Hijazi Z; Thomas L; Alexander JH; Amerena J; Hanna M; Keltai M; Lanas F; Lopes RD; Lopez-Sendon J; Granger CB; Wallentin L
    Eur Heart J; 2012 Nov; 33(22):2821-30. PubMed ID: 22933567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial.
    Rao MP; Vinereanu D; Wojdyla DM; Alexander JH; Atar D; Hylek EM; Hanna M; Wallentin L; Lopes RD; Gersh BJ; Granger CB;
    Am J Med; 2018 Mar; 131(3):269-275.e2. PubMed ID: 29122636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of apixaban for venous and arterial thromboembolic disease.
    Prom R; Spinler SA
    Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
    Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D
    Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
    Lam S
    Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH
    Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.